ADPT — Adaptive Biotechnologies Corp

—
Nasdaq · Health Care · Biotechnology · CIK 1478320 ·
Last close
$28.49
Market Cap
$4.61B
52W High
$32.21
52W Low
$12.00
ADV30
2,184,826
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 83,902,000 63,969,000 -457,000 2,876,000 683,120,000 75,615,000 499,229,000
Jun 2026 71,553,000 51,388,000 -15,770,000 -39,788,000 640,678,000 169,873,000 490,016,000
Mar 2026 70,874,000 52,166,000 -19,206,000 -20,033,000 505,943,000 77,581,000 281,702,000
Dec 2025 71,681,000 53,457,000 -12,773,000 -13,579,000 512,736,000 70,495,000 287,735,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-4,277,000
Investing CF
$-167,646,000
Financing CF
$192,520,000
CapEx
$-4,545,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.45
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,420,268,000
Inventory
$10,055,000
Receivables
$66,671,000
ST Investments
$223,339,000
EBIT TTM
$-61,689,000
Pretax Income TTM
$-70,729,000
Interest Exp TTM
$9,040,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$298,009,984
EBITDA
$-32,873,000
Free Cash Flow
$14,434,250
Enterprise Value
$4,647,004,672
Total Cash
$298,953,984
Total Debt
$408,971,008
Shares Out
161,876,694
Trailing EPS
$-0.45
Book Value
$1.09
ROE
-36.4%
ROA
-5.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 276,976,000 -57,123,000 -59,499,000 512,736,000 287,735,000 218,793,000 -45,986,000
Dec 2024 178,957,000 -155,344,000 -159,492,000 539,376,000 336,891,000 202,709,000 -95,212,000
Dec 2023 170,276,000 -201,606,000 -225,250,000 661,134,000 352,856,000 308,399,000 -156,324,000
Dec 2022 185,308,000 -200,186,000 -200,191,000 856,617,000 392,519,000 464,165,000 -183,945,000

TTM Snapshot

Revenues TTM
$308,081,000
NetIncome TTM
$-63,854,000
OpCashFlow TTM
—
Assets (Latest)
$640,678,000
Forward EPS
$-0.18

Max Pain — expiry 2027-01-15

max pain strike: $15.00 · spot: $28.46 · call oi: 2,528 · put oi: 150
Expected Move to 2027-01-15: ±$7.00 (24.60%) — implied range $21.46 – $35.46 · ATM straddle on $30.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CRSP CRISPR Therapeutics AG $3.89B $40.15 —
SRRK Scholar Rock Holding Corp $5.50B $45.08 —
TARS Tarsus Pharmaceuticals, Inc. $3.86B $78.20 —
RLAY Relay Therapeutics, Inc. $3.64B $16.47 —
IOVA IOVANCE BIOTHERAPEUTICS, INC. $3.48B $7.53 —

News headlines (Yahoo Finance, 1h cache)

Adaptive Biotechnologies Highlights clonoSEQ’s Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026
2026-11-18 08:00 · Yahoo
DNA Sequencing - Global Strategic Business Report: Secure Share of a US$17.1 Billion Market by 2030 as Eppendorf, Adaptive Biotechnologies, BGI Genomics, and Annoroad Reshape Competition
2026-11-11 14:23 · Yahoo
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
2026-11-10 21:05 · Yahoo
Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?
2026-11-10 13:15 · Yahoo
Adaptive Biotechnologies (ADPT) Reported Mixed Q3 Results, Is The Stock Fully Valued?
2026-11-08 00:19 · Yahoo
Adaptive (ADPT) Q3 2026 Earnings Call Transcript
2026-11-05 15:13 · Yahoo
Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable Quarter ...
2026-11-05 07:14 · Yahoo
Adaptive Biotechnologies Q3 Earnings Call Highlights
2026-11-05 00:14 · Yahoo
Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates
2026-11-04 23:45 · Yahoo
Ionis' Tryngolza Gets EU Approval for Severe Hypertriglyceridemia
2026-11-18 16:34 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.